Co-Diagnostics Inc. CODX shares dropped 28.26% to $0.46 in pre-market trading on Tuesday, wiping out the gains from Monday’s 80.76% surge, which had closed at $0.64, according to Benzinga Pro data.Check out the current price of CODX stock here.Strategic Partnership Fails to Sustain MomentumThe molecular diagnostics firm revealed it has signed a Memorandum of Understanding with a Saudi Arabian partner to potentially create a joint venture aimed at developing and distributing its Co-Dx™ PCR platform technolog ...

These dividend payers cranked up their payouts over the past decade, and they could do it again.Are you more interested in overall gains or generating a large stream of passive income? If you're not sure, I've got great news. It doesn't matter. Filling your portfolio with dividend payers is one of the most effective ways to outperform the overall stock market, according to over 50 years of historical data.Between 1973 and 2024, dividend-paying stocks in the benchmark S&P 500 index delivered a 9.2% average a ...

Shares of New Fortress Energy Inc. NFE rose sharply in pre-market trading after the company announced a long-term gas supply agreement with the Puerto Rican government.New Fortress said it reached an agreement on contract terms with the Third-Party Procurement Office and the Puerto Rico Public-Private Partnerships Authority for the long-term supply of liquefied natural gas to Puerto Rico.New Fortress Energy shares jumped 41% to $2.82 in the pre-market trading session.Here are some other stocks moving in pre ...

Markets are probably getting the rate cut they so badly want this week, and a lot of stocks have already rallied on the anticipation. But a few areas of the market might still have room to run after the Fed decision, a chief strategist told Business Insider on Tuesday.Liz Thomas, head of investment strategy at SoFi Technologies, sees three sectors in particular poised to rally as borrowing costs come down. Speaking with Business Insider, Thomas made it clear that she believes investors have reacted approp ...

I grant Medpace (NASDAQ: MEDP ) a buy rating. I am of the opinion that there are substantial grounds to believe that the company will continue to generate value for its investors. To begin with, the companyDaniel Mellado is an economist from Carabobo University with a Master's Degree in Statistics from Simon Bolivar University, both obtained in Venezuela.Daniel worked analyzing the agricultural commodity market and the financial investment portfolio for an agribusiness group. Then, he managed two teams, one ...

Market Analysis by covering: Alnylam Pharmaceuticals Inc, DexCom Inc, Veeva Systems Inc Class A, BlackRock Health Sciences Trust II. Read 's Market Analysis on Investing.com ...

Accessibility StatementSkip Navigation FUTR Rolls Out Closed Beta of AI Agent App That Pays Consumers for Their Data The app allows users to create a personalized AI Agent, access a secure digital vault, and earn FUTR Utility Tokens through an embedded wallet built on Coinbase's BASE blockchain. From tracking passport expiries and health card renewals to storing home insurance details, the AI Agent is built to simplify daily life while rewarding users for their data. The company says the new personalized AI ...

HAMPTON, N.J., Sept. 17, 2025 (GLOBE NEWSWIRE) -- Celldex (NASDAQ:CLDX) announced today new data demonstrating rapid and strong efficacy regardless of baseline immunoglobulin E (IgE) levels in patients with chronic spontaneous urticaria (CSU), an immune-related condition driven by mast cell activation. Barzolvolimab specifically targets mast cells by binding the receptor tyrosine kinase KIT with high specificity and potently inhibiting its activity, which is required for mast cell function and survival. The ...

Rapid and sustained efficacy regardless of baseline IgE levels in patients with CSUHAMPTON, N.J., Sept. 17, 2025 (GLOBE NEWSWIRE) -- Celldex (NASDAQ:CLDX) announced today new data demonstrating rapid and strong efficacy regardless of baseline immunoglobulin E (IgE) levels in patients with chronic spontaneous urticaria (CSU), an immune-related condition driven by mast cell activation. Barzolvolimab specifically targets mast cells by binding the receptor tyrosine kinase KIT with high specificity and potently ...

The stock has soared in the triple-digits over the past decade.When you think of adding growth to your portfolio, you may immediately envision technology stocks. After all, names like Nvidia and Meta Platforms have driven stock market gains over the past couple of years. Technology stocks are fantastic growth players, but it's important to remember that they aren't the only option for growth-oriented investors.Another industry that offers you a chance to supercharge your portfolio is biotech. Here, you'll f ...